Cencora (COR) Set to Announce Earnings on Wednesday

Cencora (NYSE:COR - Get Free Report) will post its quarterly earnings results before the market opens on Wednesday, November 6th. Analysts expect Cencora to post earnings of $3.21 per share for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.18 by $0.16. The company had revenue of $74.20 billion for the quarter, compared to analysts' expectations of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. Cencora's quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.92 earnings per share. On average, analysts expect Cencora to post $14 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Cencora Price Performance

Shares of COR stock opened at $231.79 on Wednesday. The business's fifty day moving average is $231.91 and its 200 day moving average is $230.73. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The stock has a market cap of $46.23 billion, a price-to-earnings ratio of 25.36, a PEG ratio of 1.40 and a beta of 0.44. Cencora has a twelve month low of $182.75 and a twelve month high of $247.66.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on COR. Robert W. Baird lowered their price target on shares of Cencora from $287.00 to $283.00 and set an "outperform" rating for the company in a research report on Friday, September 6th. StockNews.com cut Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Leerink Partners cut their price target on Cencora from $277.00 to $275.00 and set an "outperform" rating on the stock in a research note on Monday, October 7th. JPMorgan Chase & Co. lifted their price objective on Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a research note on Wednesday, August 21st. Finally, Evercore ISI cut their target price on Cencora from $270.00 to $250.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 8th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $259.44.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares in the company, valued at $67,223,750.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Chairman Steven H. Collis sold 21,509 shares of the company's stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares in the company, valued at $67,223,750.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of Cencora stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the transaction, the insider now owns 19,980,000 shares in the company, valued at $4,806,388,800. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,461,153 shares of company stock valued at $1,073,075,720. Insiders own 15.80% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.